Ushering in a new era of fit-for-purpose clinical endpoints for Rett syndrome [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
As much of a trial's success depends on the ability of outcome measures to assess features most significant to the disease, experts say clinical studies for the rare disorder Rett syndrome need better measures to objectively confirm symptom improvement. Rett syndrome is a rare X-linked dominant disorder caused by a mutation in the MECP2 gene on the X chromosome. The condition, which is almost exclusively found in females, goes unnoticed for the first 6–18 months of life, and then slowly affects brain development, resulting in severe physical and mental impairments. In recent times, there have been clinical advances in the Rett syndrome therapeutics space. In March 2023, Acadia Pharmaceuticals'Daybue (trofinetide) became the first and only US FDA-approved treatment for Rett syndrome. However, in January 2024, another late-stage drug, Anavex Life Sciences' ANAVEX2-73 (blarcamesine), failed in a pivotal Phase III study, tanking the company's stock by more than 36%. With an endgame
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Pharmaceuticals to Participate at Upcoming Investor ConferencesBusiness Wire
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals: Proving The Naysayers Wrong [Seeking Alpha]Seeking Alpha
ACAD
Earnings
- 11/6/24 - Beat
ACAD
Sec Filings
- 11/20/24 - Form 8-K
- 11/19/24 - Form 4
- 11/19/24 - Form 4
- ACAD's page on the SEC website